-transparent.png){kind=logo}
The anti-arrhythmic properties of a new drug, lorcainide, have been evaluated. Lorcainide is highly efficient for the treatment of ventricular arrhythmias, especially ventricular extrasystoles and recurrent ventricular tachycardia. It is also efficient in the treatment of supraventricular extrasystoles and repetitive auricular tachycardia. It is ineffective in cases of auricular fibrillation and flutter. The drug also has effective anti-arrhythmic properties when administered orally. It has a small negative inotropic effect which was not clinically relevant in the patient group studied. Side effects were within acceptable limits and essentially consist of dizziness, tremor and blurring of vision, occurring only during rapid i.v. injection and depending upon the speed of injection.
H Kesteloot, and
R Stroobandt
January 1981,
Acta cardiologica,
H Kesteloot, and
R Stroobandt
April 1980,
Minerva medica,
H Kesteloot, and
R Stroobandt
December 1981,
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
H Kesteloot, and
R Stroobandt
February 1980,
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
H Kesteloot, and
R Stroobandt
September 1970,
Minerva medica,
H Kesteloot, and
R Stroobandt
December 1975,
Minerva cardioangiologica,
H Kesteloot, and
R Stroobandt
March 1961,
Boletin de la Asociacion Medica de Puerto Rico,
H Kesteloot, and
R Stroobandt
January 1977,
Acta paediatrica Belgica,
H Kesteloot, and
R Stroobandt
January 1972,
Transactions of the American Clinical and Climatological Association,
